Navdeep Singh, MD
Pulmonary Disease · Castro Valley, CANPI 1770547192
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $897 of the $1,259 with a category attached, or 71.2%. 8 manufacturers reported payments, led by Johnson & Johnson at 52.6% of the total. 2025 is the largest year on record at $405, 3.9 times the $103 reported in 2019. That places this record below the midpoint for pulmonary disease clinicians in CA, where the typical reported total is $1,248.
Across 15 payments — averaging $83.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$663
- Lumenis BE Inc$321
- Covidien LP$103
- Medical Device Business Services, Inc.$53
- AbbVie$51
- Ceribell, Inc.$32
- plus $35 from 2 others
What the payments were for
- Travel & lodging$36229%
- Food & beverage$89771%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 6 | $663 |
| Lumenis BE Inc | 1 | $321 |
| Covidien LP | 1 | $103 |
| Medical Device Business Services, Inc. | 3 | $53 |
| AbbVie | 1 | $51 |
| Ceribell, Inc. | 1 | $32 |
| Novo Nordisk | 1 | $18 |
| Acell, Inc. | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Monarch Platform$471
- M22$321
- N/A$159
How this compares
$1,259 in reported general payments places this provider in the 50th percentile of 1,261 pulmonary disease providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 259 | $206,542 |
| OfevNintedanib Esylate | 12 | $151,772 |
| Breo ElliptaFluticasone/Vilanterol | 91 | $57,483 |
| Spiriva RespimatTiotropium Bromide | 47 | $41,960 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 43 | $29,542 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 16 | $11,753 |
| SymbicortBudesonide/Formoterol Fumarate | 30 | $9,354 |
| Spiriva HandihalerTiotropium Bromide | 14 | $7,964 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 16 | $7,448 |
| Incruse ElliptaUmeclidinium Bromide | 21 | $7,178 |
| DuleraMometasone/Formoterol | 11 | $4,299 |
| Arnuity ElliptaFluticasone Furoate | 14 | $4,085 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 88 | $2,375 |
| Ventolin HfaAlbuterol Sulfate | 26 | $1,991 |
| Montelukast Sodium | 99 | $1,352 |
Paid to pharmacies, not to this prescriber.
Other pulmonary disease in Castro Valley
- Samuel LouieSacramento$2.8M
- Shyamsunder SubramanianTracy$1.5M
- Toby MaherLos Angeles$1.3M
- Rajkumar DasguptaPasadena$930K
- Hoang leFountain Valley$814K
- Kevin FussellEncinitas$788K
- Revati ShreeniwasStanford$726K
- David PhamWestminster$571K
- Vijay BalasubramanianFresno$529K
- Victor TapsonLos Angeles$514K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.